HSIC vs REPL
Henry Schein Inc (HSIC) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
REPL does not have a complete income-statement cache yet.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. REPL currently screens at market cap $825.7M.
Not investment advice. Open the HSIC and REPL stock pages for the full models.
Not investment advice.